New research reveals that patients who discontinue new GLP-1 drugs like Mounjaro or Wegovy may regain reduced body mass at a significantly accelerated pace than those who halt traditional diet and exercise regimens.
Research printed in a major medical journal shows that while overweight people can lose a large proportion of their total mass while on the medication, the mass comes back at an estimated rate of nearly a kilo each month once they quit.
"People purchasing such medications should be aware of the danger of rapid rebound weight gain when the therapy concludes," warns researcher Dr. Susan Jebb.
That rate of recovery implies a reversion to original weight within about a year and a half.
Weighing Therapies
The research, which reviewed dozens of trials involving over 9,000 of patients, contrasted the results of these new drugs with older methods.
Researchers point out that individuals who lose weight through lifestyle changes alone usually have a less rapid weight regain—perhaps 0.1 kg a month—once they finish.
The Reason for the Rapid Regain
Nutrition scientists believe the mechanism of the jabs accounts for the heightened rebound.
The injections copy a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Sustained high doses of the hormone concentrations far above than the body's typical production could lead to the system to produce less of its own natural GLP-1, and could lessen responsiveness to its effects," explained Dr. Adam Collins, a dietetics researcher.
"Stopping of this hormone supplement leads to appetite is uncontrolled, making overeating far more likely."
A Chronic Issue?
Health authorities advise the injections for individuals with obesity-related health risks, alongside recommended lifestyle changes.
A number of clinicians argue that, given the high risk of relapse, the therapy is often long-term.
This view is reinforced by drug manufacturers, who say that the findings "underscore the long-term character of obesity," similar to managing conditions like high blood pressure.
User Experiences
Individuals who have stopped the jabs describe a sudden return of appetite.
"I experienced a switch activating and I was suddenly starving," recalled one woman.
This difficulty is worsened if individuals have not established lasting dietary or behavioural modifications during treatment.
Widespread Adoption
Survey data indicate that millions of adults in the UK have tried these injections in the last 12 months, with desire being substantial.
- Adoption is more common among females compared to men.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion obtain the medications through private prescriptions rather than the NHS.
Finally, researchers caution that while GLP-1 drugs are powerful tools for weight loss, they are not a magic cure and maintained weight loss likely depends on ongoing behavioural changes.